$40.00
0.38%
Nasdaq, Aug 22, 10:01 pm CET
ISIN
US38870X1046
Symbol
LENZ

Graphite Bio Inc Stock price

$40.00
+7.02 21.29% 1M
+17.47 77.54% 6M
+11.13 38.55% YTD
+17.78 80.02% 1Y
+22.96 134.77% 3Y
-47.56 54.31% 5Y
-47.56 54.31% 10Y
-47.56 54.31% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.15 0.38%
ISIN
US38870X1046
Symbol
LENZ
Industry

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$931.4m
Net debt
positive
Cash
$209.5m
Shares outstanding
28.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
228.2 | 145.8
EV/Sales
186.3 | 119.0
EV/FCF
negative
P/B
5.5
Dividends
DPS
$7.21
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
-308.1% | -37.0%
Increased
1 Year
Financials (TTM | estimate)
Revenue
$5.0m | $7.8m
EBITDA
$-61.9m | $-79.0m
EBIT
$-62.0m | $-85.7m
Net Income
$-52.4m | $-82.9m
Free Cash Flow
$-47.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
22.8% | -35.0%
EBIT
23.5% | -46.2%
Net Income
27.5% | -66.5%
Free Cash Flow
52.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,237.4% | -1,009.7%
EBIT
-1,239.2%
Net
-1,048.0% | -1,059.0%
Free Cash Flow
-958.0%
Financial Health
Equity Ratio
94.8%
Return on Equity
-24.4%
ROCE
-29.9%
ROIC
-
Debt/Equity
0.0
More
EPS
$-1.9
FCF per Share
$-1.7
Short interest
24.8%
Employees
-
Rev per Employee
-
Show more

Is Graphite Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Graphite Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Graphite Bio Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Graphite Bio Inc forecast:

Buy
93%
Hold
7%

Financial data from Graphite Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
5 5
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
2% 2%
795%
- Research and Development Expense 27 27
37% 37%
544%
-62 -62
23% 23%
-1,237%
- Depreciation and Amortization 0.09 0.09
90% 90%
2%
EBIT (Operating Income) EBIT -62 -62
24% 24%
-1,239%
Net Profit -52 -52
28% 28%
-1,048%

In millions USD.

Don't miss a Thing! We will send you all news about Graphite Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Graphite Bio Inc Stock News

Neutral
GlobeNewsWire
24 days ago
VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States
Positive
The Motley Fool
25 days ago
Lenz (LENZ) Q2 Revenue Jumps 604%
Neutral
GlobeNewsWire
26 days ago
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and prepared to initiate sales and marketing activities immediately upon approval Executed multiple international license and commercialization agreements for LNZ100 including over $195 million in upfront and milestone payments together with doubl...
More Graphite Bio Inc News

Company Profile

Graphite Bio, Inc. operates as a clinical-stage gene editing company. It focuses on therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo in June 2017 and is headquartered in South San Francisco, CA.

Head office United States
CEO Evert Schimmelpennink
Founded 2017
Website lenz-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today